We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+10.72%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.85B
AUM Growth
+$338M
Cap. Flow
+$79.4M
Cap. Flow %
1.36%
Top 10 Hldgs %
45.51%
Holding
707
New
76
Increased
198
Reduced
354
Closed
64

Top Buys

Rank Stock Value
1
TER icon
Teradyne
TER
+$60.1M
2
TSLA icon
Tesla
TSLA
+$32.1M
3
TSEM icon
Tower Semiconductor
TSEM
+$29.6M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$29M
5
PDD icon
Pinduoduo
PDD
+$28.1M

Top Sells

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$77.7M
2
BE icon
Bloom Energy
BE
+$53.1M
3
HOOD icon
Robinhood
HOOD
+$24.9M
4
SAP icon
SAP
SAP
+$24.1M
5
BIDU icon
Baidu
BIDU
+$21.5M

Sector Composition

Rank Sector Weight
1 Technology 51.21%
2 Communication Services 15.38%
3 Consumer Discretionary 13.01%
4 Healthcare 6.62%
5 Consumer Staples 4.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
501
Novavax
NVAX
$1.21B
$21.5K ﹤0.01%
3,193
-301
-9% -$2.27K
IOVA icon
502
Iovance Biotherapeutics
IOVA
$2.04B
$21.4K ﹤0.01%
7,830
+45
+0.6% +$104
SILA
503
DELISTED
Sila Realty Trust
SILA
$21.4K ﹤0.01%
916
-4
-0.4% -$94
SANA icon
504
Sana Biotechnology
SANA
$882M
$21.3K ﹤0.01%
5,234
-332
-6% -$1.49K
UMH
505
UMH Properties
UMH
$1.34B
$21.3K ﹤0.01%
1,337
-6
-0.4% -$90
ERAS icon
506
Erasca
ERAS
$6.15B
$20.7K ﹤0.01%
5,574
-459
-8% -$1.29K
VRE
507
DELISTED
Veris Residential
VRE
$20.7K ﹤0.01%
1,393
+16
+1% +$236
NTLA icon
508
Intellia Therapeutics
NTLA
$1.51B
$20.5K ﹤0.01%
2,275
-35
-2% -$482
ABCL icon
509
AbCellera Biologics
ABCL
$1.65B
$20.1K ﹤0.01%
5,882
-547
-9% -$2.44K
GLUE icon
510
Monte Rosa Therapeutics
GLUE
$1.82B
$20.1K ﹤0.01%
1,279
-38
-3% -$512
DAWN
511
DELISTED
Day One Biopharmaceuticals
DAWN
$18.8K ﹤0.01%
2,017
-187
-8% -$1.56K
ALMS
512
Alumis Inc
ALMS
$3.36B
$18.6K ﹤0.01%
1,910
-174
-8% -$1.22K
TBPH icon
513
Theravance Biopharma
TBPH
$873M
$18.6K ﹤0.01%
995
-88
-8% -$1.46K
CSR
514
Centerspace
CSR
$952M
$18.6K ﹤0.01%
279
-1
-0.4% -$63
RAPT
515
DELISTED
RAPT Therapeutics
RAPT
$18.4K ﹤0.01%
+544
New +$16.9K
ABUS icon
516
Arbutus Biopharma
ABUS
$847M
$18.2K ﹤0.01%
3,778
-346
-8% -$1.56K
BCAX
517
Bicara Therapeutics
BCAX
$1.7B
$18.1K ﹤0.01%
+1,076
New +$18.4K
CRMD icon
518
CorMedix
CRMD
$564M
$18K ﹤0.01%
1,548
-58
-4% -$641
ELVN icon
519
Enliven Therapeutics
ELVN
$3.78B
$17.9K ﹤0.01%
1,165
-109
-9% -$2.17K
KURA icon
520
Kura Oncology
KURA
$793M
$17.8K ﹤0.01%
1,710
-157
-8% -$1.65K
YUMC icon
521
Yum China
YUMC
$15.7B
$17.7K ﹤0.01%
+370
New +$16.9K
JBGS
522
JBG SMITH
JBGS
$846M
$17.4K ﹤0.01%
1,023
-184
-15% -$3.48K
MESO
523
Mesoblast
MESO
$1.83B
$17.4K ﹤0.01%
964
-52
-5% -$895
ESPR
524
DELISTED
Esperion Therapeutics
ESPR
$17.4K ﹤0.01%
4,696
+358
+8% +$1.16K
PDM
525
Piedmont Realty Trust
PDM
$1.24B
$17.1K ﹤0.01%
2,056
-10
-0.5% -$83
19 20
21
22 23

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GF Fund Management's Q4 2025 Portfolio in Review

As of Q4 2025, GF Fund Management held 707 positions worth $5.85B, up 6.1% from $5.51B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

GF Fund Management's Q4 2025 filing shows 76 new, 198 increased, 354 reduced and 64 closed positions. Its largest new stake was Teradyne: 350,137 shares worth $67.8M. The largest sale was Broadcom, an estimated $77.7M.

By sector, the portfolio is most concentrated in Technology at 51% of assets, up from 49% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q4 2025 buy was Teradyne: 350,137 shares worth $67.8M.
  • GF Fund Management added most to Tesla in Q4 2025, an estimated $32.1M increase.
  • GF Fund Management's biggest Q4 2025 reduction was Broadcom, cutting an estimated $77.7M.
  • GF Fund Management fully exited Baidu in Q4 2025, selling an estimated $21.5M.
  • GF Fund Management's ten largest holdings make up 46% of its $5.85B portfolio in Q4 2025.
  • GF Fund Management opened 76 new positions and closed 64 in Q4 2025.
  • GF Fund Management's portfolio value rose 6.1% quarter-over-quarter to $5.85B.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.